BIO Bio-Rad Laboratories Inc - Class A

  1. Stocks
  2. Healthcare
  3. NYSE: BIO

Price (delayed)

$369.32

Market cap

$9.87B

P/E Ratio

45.88

Dividend/share

N/A

EPS

$8.05

Enterprise value

$10.73B

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 82
Relative Valuation: Rel. Valuation: 23
Relative Profitability: Rel. Profitability: 41

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...

Highlights
The equity has grown by 4.7% from the previous quarter
The debt has declined by 2.6% year-on-year
The EPS has increased by 38% from the previous quarter but it has decreased by 32% YoY
The net income rose by 32% QoQ but it fell by 30% YoY
The company's quick ratio fell by 36% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.bio-rad.com
Peers: TMO BDX HBIO A

Key stats

What are the main financial stats of BIO

BIO stock price

How has the Bio-Rad Laboratories stock price performed over time
Intraday
0.15%
1 week
-4.35%
1 month
3.67%
1 year
29.18%
YTD
21.89%
QTD
25.79%

Financial performance

How have Bio-Rad Laboratories's revenue and profit performed over time
Revenue
$2.59B
Gross profit
$1.34B
Operating income
$53.1M
Net income
$222.4M
Gross margin
51.9%
Net margin
8.6%
BIO's operating margin has dropped by 76% year-on-year and by 4.5% since the previous quarter
BIO's operating income has dropped by 76% year-on-year and by 8% since the previous quarter
The net income rose by 32% QoQ but it fell by 30% YoY
The net margin is up by 32% since the previous quarter but it has declined by 31% year-on-year

Price vs fundamentals

How does BIO's price correlate with its fundamentals

Growth

What is Bio-Rad Laboratories's growth rate over time

Valuation

What is Bio-Rad Laboratories stock price valuation
BIO P/E details
P/E
45.88
P/B
1.38
P/S
3.81
EV/EBIT
26.87
EV/EBITDA
26.87
EV/Sales
4.14
The EPS has increased by 38% from the previous quarter but it has decreased by 32% YoY
BIO's P/B is 25% above its last 4 quarters average of 1.1 and 6% above its 5-year quarterly average of 1.3
The equity has grown by 4.7% from the previous quarter
The stock's price to sales (P/S) is 27% more than its last 4 quarters average of 3.0 but 7% less than its 5-year quarterly average of 4.1

Efficiency

How efficient is Bio-Rad Laboratories business performance
The ROS has increased by 47% from the previous quarter but it has decreased by 21% YoY
The company's return on invested capital rose by 45% QoQ but it fell by 19% YoY
The ROE is up by 33% since the previous quarter but it is down by 30% year-on-year
Bio-Rad Laboratories's ROA has decreased by 31% YoY but it has increased by 29% from the previous quarter

Dividends

What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIO.

Financial health

How did Bio-Rad Laboratories financials performed over time
The company's current ratio fell by 39% YoY and by 2.2% QoQ
The company's quick ratio fell by 36% YoY
The debt is 81% smaller than the equity
Bio-Rad Laboratories's debt to equity has decreased by 5% from the previous quarter and by 5% YoY
The equity has grown by 4.7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.